Baidu
map

Crit Care:危重病成年患者临床可用肾脏标志物的评价分析!

2017-04-06 xing.T MedSci原创

将一个功能标志物(sCysC)和肾小管损伤标志物(uNAG)进行组合可以显著增加AKI检测的诊断性能,并得到额外的ICU死亡预后信息。

尽管血清胱抑素C(sCysC)、尿N-乙酰-β-D-氨基葡萄糖苷酶(uNAG)和尿白蛋白/肌酐比值(uACR)在临床上是可用的,但是其在急性肾损伤(AKI)检测和预后预测方面的最优组合尚不清楚。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,研究人员旨在评估这些生物标志物及其可能的组合在检测危重病成人的AKI和预测重症监护病房(ICU)死亡方面的性能。

这是一项在三级医院混合医疗外科ICU进行的多中心、前瞻性研究。共有1084名入住ICUs的成年危重患者被纳入研究。研究人员评估了入住ICU时个别生物标志物(sCysC、uNAG和uACR)的测量及其组合在AKI诊断及预后预测上的使用情况。

研究人员计算了sCysC、uNAG和uACR的ROCs曲线下面积(AUC),对于总AKI(分别为0.738、0.650和0.683),对于严重的AKI(分别为0.839、0.706和0.771)以及ICU死亡(分别为0.727、0.793和0.777)。sCysC与uNAG的组合在总的和重度AKI的诊断准确性上要比单个生物标志物或其他两两组合(uNAG与uACR或sCysC与uACR)要显著升高。对于入住ICU时总AKI、严重的AKI和ICU死亡的检测,sCysC与uNAG的组合得到的ROCS-AUC分别为0.756、0.863和0.811;阳性预测值分别为0.71、0.31和0.17;阴性预测值分别为0.81、0.97和0.98。此外,该组合可以显著提高临床模型AKI检测和ICU死亡预测的精度。该组合的比较性能通过 bootstrap内部验证得到了进一步证实。

将一个功能标志物(sCysC)和肾小管损伤标志物(uNAG)进行组合可以显著增加AKI检测的诊断性能,并得到额外的ICU死亡预后信息。

原始出处:


Yujun Deng, et al. Evaluation of clinically available renal biomarkers in critically ill adults: a prospective multicenter observational study.Critical Care.2017. https://ccforum.biomedcentral.com/articles/10.1186/s13054-017-1626-0

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840989, encodeId=256a184098919, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Sep 28 06:00:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690438, encodeId=efec169043830, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Fri Dec 29 07:00:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444201, encodeId=c9d714442012a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Apr 08 10:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185619, encodeId=0a08185619ba, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Fri Apr 07 00:02:33 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185608, encodeId=565f1856088f, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Thu Apr 06 20:33:14 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840989, encodeId=256a184098919, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Sep 28 06:00:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690438, encodeId=efec169043830, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Fri Dec 29 07:00:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444201, encodeId=c9d714442012a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Apr 08 10:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185619, encodeId=0a08185619ba, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Fri Apr 07 00:02:33 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185608, encodeId=565f1856088f, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Thu Apr 06 20:33:14 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840989, encodeId=256a184098919, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Sep 28 06:00:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690438, encodeId=efec169043830, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Fri Dec 29 07:00:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444201, encodeId=c9d714442012a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Apr 08 10:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185619, encodeId=0a08185619ba, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Fri Apr 07 00:02:33 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185608, encodeId=565f1856088f, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Thu Apr 06 20:33:14 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-08 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840989, encodeId=256a184098919, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Sep 28 06:00:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690438, encodeId=efec169043830, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Fri Dec 29 07:00:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444201, encodeId=c9d714442012a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Apr 08 10:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185619, encodeId=0a08185619ba, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Fri Apr 07 00:02:33 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185608, encodeId=565f1856088f, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Thu Apr 06 20:33:14 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-07 1dd8f26bm82(暂无匿称)

    好资源

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1840989, encodeId=256a184098919, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Sep 28 06:00:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690438, encodeId=efec169043830, content=<a href='/topic/show?id=fdb336e49bb' target=_blank style='color:#2F92EE;'>#危重病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36749, encryptionId=fdb336e49bb, topicName=危重病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27f729051889, createdName=xinmeili, createdTime=Fri Dec 29 07:00:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444201, encodeId=c9d714442012a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Apr 08 10:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185619, encodeId=0a08185619ba, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Fri Apr 07 00:02:33 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185608, encodeId=565f1856088f, content=好资源, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Thu Apr 06 20:33:14 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-06 1dd8f26bm82(暂无匿称)

    好资源

    0

相关资讯

Stroke:危重病相关的脑微出血有啥特征?

在该研究中,研究人员描述了重大疾病患者大脑白质发生了一种独特的微出血现象。尽管这些患者大脑微出血的具体原因尚不清楚,但其发病机制可能涉及低氧血症,因为这些患者的脑部微出血与高厡暴露脑部微出血患者所描述的相类似。

Baidu
map
Baidu
map
Baidu
map